A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Gynecological Malignancies

Interventions

DRUG

BL-M07D1

Administration by intravenous infusion

Trial Locations (1)

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY